UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 275

Sortiert nach

Deep learning body-composition analysis of clinically acquired CT-scans estimates creatinine excretion with high accuracy in patients and healthy individuals

Scientific reports, 2022-05, Vol.12 (1), p.9013-9013, Article 9013

2022

Volltextzugriff (PDF)

Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography–triple quadrupole mass spectrometry

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2008-05, Vol.867 (2), p.205-212

2008

Volltextzugriff (PDF)

Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment

European journal of clinical pharmacology, 2016-06, Vol.72 (6), p.645-653

2016

Volltextzugriff (PDF)

A real or apparent decrease in glomerular filtration rate in patients using olaparib?

European journal of clinical pharmacology, 2021-02, Vol.77 (2), p.179-188

2021

Volltextzugriff (PDF)

Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients

Cancer chemotherapy and pharmacology, 2023-06, Vol.91 (6), p.447-456

2023

Volltextzugriff (PDF)

Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine

Cancer chemotherapy and pharmacology, 2012, Vol.69 (1), p.25-33

2012

Volltextzugriff (PDF)

Development and validation of a liquid chromatography–tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs

Biomedical chromatography, 2018-04, Vol.32 (4), p.n/a

2018

Volltextzugriff (PDF)

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours

British journal of cancer, 2014-05, Vol.110 (10), p.2441-2449

2014

Volltextzugriff (PDF)

Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction

Cancer chemotherapy and pharmacology, 2014, Vol.73 (1), p.113-124

2014

Volltextzugriff (PDF)

Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature

Cancer chemotherapy and pharmacology, 2022-07, Vol.90 (1), p.97-104

2022

Volltextzugriff (PDF)

The use of microtracers in food‐effect trials: An alternative study design for toxic drugs with long half‐lives exemplified by the case for alectinib

Clinical and translational science, 2023-12, Vol.16 (12), p.2557-2564

2023

Volltextzugriff (PDF)

Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy

Cancer chemotherapy and pharmacology, 2015-04, Vol.75 (4), p.763-772

2015

Volltextzugriff (PDF)

Development and validation of a quantitative assay for the measurement of two HIV-fusion inhibitors, enfuvirtide and tifuvirtide, and one metabolite of enfuvirtide (M-20) in human plasma by liquid chromatography–tandem mass spectrometry

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2006-06, Vol.837 (1), p.49-58

2006

Volltextzugriff (PDF)

Identification and profiling of circulating metabolites of atazanavir, a HIV protease inhibitor

Drug metabolism and disposition, 2009-09, Vol.37 (9), p.1826

2009

Volltextzugriff (PDF)

A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68Ga-DOTATATE in patients without neuroendocrine tumors

EJNMMI research, 2021-08, Vol.11 (1), p.73-73, Article 73

2021

Volltextzugriff (PDF)

High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy

British journal of cancer, 2006-05, Vol.94 (9), p.1226-1230

2006

Volltextzugriff (PDF)

A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2009-11, Vol.877 (29), p.3625-3630

2009

Volltextzugriff (PDF)

Development and validation of an integrated LC-MS/MS assay for therapeutic drug monitoring of five PARP-inhibitors

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2020-02, Vol.1138, p.121925-121925, Article 121925

2020

Volltextzugriff (PDF)

Validation and clinical application of an LC-MS/MS method for the quantification of everolimus using volumetric absorptive microsampling

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2019-01, Vol.1104, p.234-239

2019

Volltextzugriff (PDF)

Treatment of hereditary angioedema with nanofiltered C1-esterase inhibitor concentrate (Cetor®): Multi-center phase II and III studies to assess pharmacokinetics, clinical efficacy and safety

Clinical immunology (Orlando, Fla.), 2012-03, Vol.142 (3), p.280-290

2012

Volltextzugriff (PDF)

Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC

European journal of surgical oncology, 2018-02, Vol.44 (2), p.220-227

2018

Volltextzugriff (PDF)

Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization

Cancer chemotherapy and pharmacology, 2017-12, Vol.80 (6), p.1171-1178

2017

Volltextzugriff (PDF)

Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liquid chromatography coupled with tandem mass spectrometry

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2009-02, Vol.877 (5), p.575-580

2009

Volltextzugriff (PDF)

Prospective experimental treatment of colorectal cancer patients based on organoid drug responses

ESMO open, 2021-06, Vol.6 (3), p.100103, Article 100103

2021

Volltextzugriff (PDF)

1 – 25 von 275

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid Full Text

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(254)
Mit Volltextzugriff
(248)

Publikationsform

Artikel
(271)
Tagungsberichte
(4)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Deep learning body-composition analysis of clinically acquired CT-scans estimates creatinine excretion with high accuracy in patients and healthy individuals

Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography–triple quadrupole mass spectrometry

Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment

A real or apparent decrease in glomerular filtration rate in patients using olaparib?

Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients

Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine

Development and validation of a liquid chromatography–tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours

Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction

Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature

The use of microtracers in food‐effect trials: An alternative study design for toxic drugs with long half‐lives exemplified by the case for alectinib

Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy

Development and validation of a quantitative assay for the measurement of two HIV-fusion inhibitors, enfuvirtide and tifuvirtide, and one metabolite of enfuvirtide (M-20) in human plasma by liquid chromatography–tandem mass spectrometry

Identification and profiling of circulating metabolites of atazanavir, a HIV protease inhibitor

A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68Ga-DOTATATE in patients without neuroendocrine tumors

High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy

A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry

Development and validation of an integrated LC-MS/MS assay for therapeutic drug monitoring of five PARP-inhibitors

Validation and clinical application of an LC-MS/MS method for the quantification of everolimus using volumetric absorptive microsampling

Treatment of hereditary angioedema with nanofiltered C1-esterase inhibitor concentrate (Cetor®): Multi-center phase II and III studies to assess pharmacokinetics, clinical efficacy and safety

Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC

Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization

Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liquid chromatography coupled with tandem mass spectrometry

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II)

Prospective experimental treatment of colorectal cancer patients based on organoid drug responses

Aktive Filter

Suchergebnisse filtern